Multiple myeloma (MM) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051124
Expand allThis document outlines details of PBS-subsidised elotuzumab, lenalidomide, pomalidomide and selinexor for patients with multiple myeloma (MM).
MM and listing dates
MM is a type of blood cancer.
Listing dates:
- lenalidomide - 1 November 2009
- pomalidomide - 1 August 2015
-
elotuzumab - 1 May 2022
Note: for commercial reasons, initial treatment with elotuzumab is no longer PBS-subsidised as of 1 December 2024. Continuing treatment with elotuzumab remains on the PBS to make sure continuity of the treatment for existing patients - selinexor - 1 September 2022 (moved to general line 1 October 2025)
See Written Authority Required Drugs for more details.
Enquiries
- Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated
- Transfer enquiries about prescription arrangements for selinexor to the PBS authority approvals line
The Resources page contains:
- application forms
- contact details
- FAQs from Service Officers
- restriction and item codes
- the PBS schedule
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Processing and National Demand Allocation (PaNDA)
Processing Complex Authority Required Listings
Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)
Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)
Written Authority Required Drugs